Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Thea Pharma

Status and phase: Completed; Phase 2

Conditions: Seasonal Allergic Conjunctivitis

Treatments: Drug: T1210; Drug: Olopatadine hydrochloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT01344083

LT1210-PII-04/10

Details and patient eligibility

About

The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine eye drops in the topical treatment of seasonal allergic conjunctivitis.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent
• Conjunctivitis allergic conjunctivitis

Exclusion criteria

• Severe ocular allergy
• Vernal keratoconjunctivitis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 2 patient groups

T1210

Experimental group

Treatment:

Drug: T1210

Olopatadine hydrochloride

Active Comparator group

Treatment:

Drug: Olopatadine hydrochloride